Eisai

Eisai Pharmaceuticals India Pvt. Ltd. (EIL) was incorporated in March 2007. It is a subsidiary of global Japanese pharmaceutical company, Eisai Co., Ltd., based in Tokyo, Japan.

Eisai at a Glance

Over 80 Years of history

Toyoji Naito, Eisai’s founder, established Nihon Eisai Co., Ltd. in 1941, focusing on in-house R&D to create new medicines. ‘Eisai’ (pronounced Ezai) means ‘ei; sanitation, health’ and sai; materials, product’ respectively.

FINANCIAL

FY2023 Revenue

(fiscal year ended March 31, 2024)

741.8 Billion JPY

$4.79 Billion USD

More than 40 subsidiaries

Over 11,000 Employees Worldwide

Over 11,000 employees are working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries with operations in Japan, Americas (North America), China, EMEA (Europe, the Middle East, Africa, Russia and Oceania), and Asia and Latin America.

Our Major Milestones

Incorporation of Eisai Pharmaceuticals India Pvt. Ltd.

2005

Eisai Pharmatechnology and Manufacturing Pvt. Ltd. was established. Laid foundation for the development of State-of-the-Art Facility.

2007

Eisai Knowledge Center, commenced it's operations.

2009

FDA and PMDA regulatory approvals

2011

MHRA and KFDA approvals

2012

Launch of Dayvigo. The innovative first-in-class therapy in insomnia.

2022

Launch of Fycompa & Lenvima. Integration of Multiple Sclerosis Business Unit

2017

Commencement of G-API development for generics. Merger of Indian entities to form Eisai Pharmaceuticals India Pvt. Ltd. (EIL)

2015

Start of new R&D block and early stage development

2014

WHO approvals

2013

Message from Leadership

Dear all stakeholders,

We have full function of pharmaceuticals such as Drug Substance, Research & Development, Drug production and Commercial operation across India.

We are proud of manufacturing and supplying our products with high quality and beneficial information through daily activities. We stipulate that "the Company's mission is to increase the satisfaction of patients and the people in the daily living domain, and to empower them to realize their fullest life through an hhc ecosystem developed through collaboration with other industries and groups." in our Articles of Incorporation”.

Eisai Pharmaceuticals India Pvt. Ltd. is the Research & Development oriented company which was established in India 20 years ago as a subsidiary of Eisai Co.,Ltd. In Japan. To pursuit this mission we give first thoughts to patients and the people in the daily living domain. We strive to increase the benefits that healthcare provides them and we conduct our business to meet their diversified healthcare needs worldwide. As a human health care (“hhc”) company, we develop and provide products and services that contribute to the well-being of patients and customers under any healthcare system. Human health care (“hhc”) is our basis and never ending concept at any place, any time for anyone in the world.

Mr. Kyo Toda

Managing Director
Eisai Pharmaceuticals India Pvt. Ltd.

It's our way of life at Eisai, giving first thought to patient and their families. Our mission drives us to create breakthrough solutions and medicines for them. We aim to effectively achieve social good by relieving anxiety over health and reducing health disparities.

EIL's manufacturing excellence ensures a stable supply of clinical trial material, active pharmaceutical ingredients, and finished dose formulations globally. Our commitment to the WHO to eliminate Lymphatic filariasis (LF) by manufacturing and supplying Diethylcarbamazine Citrate (DEC) tablets at zero price has made us proud of our association. We are also proud members of RE100, an initiative encouraging companies to invest in renewable energy sources.

Dr. Girish Dixit

Executive Director & Site Head - Vizag
Eisai Pharmaceuticals India Pvt. Ltd.

Board of Directors

To download our Annual return of the company Form MGT-7

Download Form MGT-7

About Eisai

Eisai Co., Ltd., was the first Japanese company to have a 100% subsidiary in the Indian pharmaceutical market.